BACKGROUND: The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval. PATIENTS AND METHODS: Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9 × 10(6) IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8(high)CD57(+) lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment. RESULTS: The multivariate analysis showed that CD8(high)CD57(+) lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients. CONCLUSION: Peripheral blood CD8(high)CD57(+) lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.
BACKGROUND: The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval. PATIENTS AND METHODS: Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9 × 10(6) IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8(high)CD57(+) lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment. RESULTS: The multivariate analysis showed that CD8(high)CD57(+) lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients. CONCLUSION: Peripheral blood CD8(high)CD57(+) lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.
Authors: Dagmar Quandt; Hans Dieter Zucht; Arno Amann; Anne Wulf-Goldenberg; Carl Borrebaeck; Michael Cannarile; Diether Lambrechts; Herbert Oberacher; James Garrett; Tapan Nayak; Michael Kazinski; Charles Massie; Heidi Schwarzenbach; Michele Maio; Robert Prins; Björn Wendik; Richard Hockett; Daniel Enderle; Mikkel Noerholm; Hans Hendriks; Heinz Zwierzina; Barbara Seliger Journal: Oncotarget Date: 2017-07-18
Authors: Ane Orrantia; Iñigo Terrén; Gabirel Astarloa-Pando; Carmen González; Alasne Uranga; Juan J Mateos-Mazón; Juan C García-Ruiz; Marta Riñón; Mercedes Rey; Silvia Pérez-Fernandez; Olatz Zenarruzabeitia; Francisco Borrego Journal: Front Immunol Date: 2021-10-05 Impact factor: 7.561